Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in Primary Immune Thrombocytopenia
NCT02718716Phase 2Completed
- Sponsor
- UCB
- Start
- Mar 2016
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of rozanolixizumab in primary immune thrombocytopenia (ITP), sponsored by UCB. Started Mar 2016; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02718716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718716.